Our research indicates that patients with NAFLD show markedly increased levels of HOMA-IR, TyG, and CRP, highlighting their potential as crucial indicators for early identification and risk assessment. This evidence concerns the gene CRP and metabolic dysfunction-associated steatotic liver disease.